Latham & Watkins represented the lender, HPS Investment Partners, in the transaction. SDC US SmilePay SPV’s (SPV), a wholly-owned special purpose subsidiary of SmileDirectClub, Inc. announced […]
SmileDirectClub’s $255 Million Debt Facility
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and […]
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger […]
CooperCompanies’ Acquisition of Cook Medical’s Reproductive Health Business
Latham & Watkins represented CooperCompanies in the transaction. CooperCompanies has announced it has signed a binding letter of intent to acquire Cook Medical’s Reproductive Health business, a manufacturer […]
Innocoll Biotherapeutics’ $125 Million Term Loan Facility
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful […]
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that […]
Silver Spike Acquisition Corp. II’s $446 Million Combination With Eleusis
Davis Polk advised Silver Spike Acquisition Corp. II on the deal, while Latham & Watkins represented Eleusis. Silver Spike Acquisition Corp. II announced its approximately $446 […]
Coherus BioSciences’ $300 Million Credit Financing with Pharmakon Advisors
Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed […]
UCB’s Acquisition of Zogenix
Covington represented UCB, while Latham & Watkins represented Zogenix on the deal. Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to […]
Medtronic’s Acquisition of Affera
Latham & Watkins represented Affer in the transaction. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has announced that it has entered into a definitive agreement […]
Royal Philips’ Acquisition of Vesper Medial
Latham & Watkins represented Vesper Medical in the transaction. Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, has signed an agreement to […]
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in […]